PTO Instructed to Allow Companies to Amend IPR-Challenged Patents

The Federal Circuit eased the ability for patent holders to amend their claims when challenged under inter partes review — a hurdle that pharmaceutical industry trade groups had previously described as unfair, ambiguous and impractical.
Source: International Pharmaceutical Regulatory Monitor